Physician profile
Daniel K Bregman
NPI 1871529982
$3,604.76
in general payments reported to CMS, 2019-2025
14 companies · $14.68 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $386 · 2021: $350 · 2022: $913 · 2023: $1,057 · 2024: $309 · 2025: $14.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,380.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,432.26 | 2019-2024 | Lensx, Argos, Acrysof Iq Panoptix Uv Iol |
| Abbvie INC. | $392.60 | 2022-2023 | Durysta |
| Ivantis, INC | $372.03 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $108.33 | 2023 | Miebo |
| Allergan, INC. | $85.48 | 2020-2021 | |
| Sight Sciences, INC. | $50.19 | 2019-2023 | Omni Surgical System |
| Johnson & Johnson Surgical Vision, INC. | $31.81 | 2021 | |
| Horizon Therapeutics Plc | $28.65 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $25.11 | 2022 | |
| Harrow Eye, LLC | $22.20 | 2024 | Vevye |
| New World Medical,INC. | $20.92 | 2024 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Shire North American Group INC | $20.50 | 2019 | |
| Boston Scientific Corporation | $14.68 | 2025 | Wavewriter Alpha Prime 16 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bregman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.